# Precision Neuroscience

> Precision Neuroscience develops thin-film cortical electrode arrays and brain-computer interface systems. Its FDA-cleared Layer 7-T supports temporary brain-surface recording, monitoring and stimulation; a permanent wireless BCI remains investigational. Clinical partnerships, an owned Texas foundry and a planned Medtronic integration underpin its route to market.

- **Founded:** 2021
- **Headquarters:** New York, United States
- **Founders:** Benjamin Rapoport (Co-founder and Chief Science Officer), Michael Mager (Co-founder and CEO), Mark Hettick (Co-founder and VP of Engineering), Demetrios Papageorgiou (Co-founder)
- **Products:** Layer 7-T Cortical Interface, Permanent wireless brain-computer interface, Precision BioMEMS
- **Notable:** FDA 510(k) clearance K242618 dated March 30, 2025, for Layer 7-T., Reported simultaneous cortical recording with 4,096 electrodes in April 2024., More than 100 patient procedures across 18 medical institutions reported September 2026.

## Products & services

- **Layer 7-T Cortical Interface** — Sterile, single-use 1,024-electrode thin-film array cleared for temporary use of less than 30 days with recording, monitoring and stimulation equipment.
- **Permanent wireless brain-computer interface** — Investigational system intended to translate neural activity into digital-device commands for people with paralysis; not available for sale in the United States.
- **Precision BioMEMS** — Wholly owned manufacturing subsidiary operating a 22,000-square-foot Texas MEMS facility to fabricate cortical arrays.

## Achievements

- FDA 510(k) clearance K242618 dated March 30, 2025, for Layer 7-T.
- Reported simultaneous cortical recording with 4,096 electrodes in April 2024.
- More than 100 patient procedures across 18 medical institutions reported September 2026.
- Research published online in Nature Biomedical Engineering in October 2025.
- Acquired an owned MEMS foundry and announced FDA Breakthrough Device designation in October 2023.

## Latest updates

- **2026-09** — Closed a $250 million Series D; reported total capital raised of $430 million.
- **2026-07** — Appointed BrainGate founder John Donoghue as scientific advisor.
- **2026-04** — Announced a UChicago Medicine research partnership.
- **2026-01** — Announced co-development partnership with Medtronic.

## Links

- Website: https://www.precisionneuro.io/
- LinkedIn: https://www.linkedin.com/company/precision-neuroscience-corporation
- Twitter/X: https://x.com/PrecisionNeuro_
- YouTube: https://www.youtube.com/@PrecisionNeuroscience
- Bluesky: https://bsky.app/profile/precisionneuro.bsky.social
- Instagram: https://www.instagram.com/precisionneuroscience
- Facebook: https://www.facebook.com/PrecisionNeuroscience/

---

Profile page: https://yespress.io/precision-neuroscience
Published by YesPress — https://yespress.io
Last updated: 2026-10-03